Outcome Notes
DISEASE PROGRESSION
Primary endpoint analysis of the PSA response rate demonstrated that 31% (4/13) were considered responders to satraplatin, with a ≥30% reduction in PSA as compared to baseline levels. A total of 46% (6/13) were considered non-responders.There was a significantly improved time to disease progression, defined by PSA and/or radiographic progression, in responders as compared to non-responders (206 vs. 35 days, HR 0.26, 95% CI, 0.02-0.24, 